HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

This study aims to determine if ziltivekimab can be used to treat people living with heart failure and inflammation in reducing the risk of cardiovascular death and heart failure events. Participants will receive either ziltivekimab or placebo (a pill with no active drug ingredient). The study drug will be given through monthly injections, using either a pre-filled syringe or a pen-injector. The trial is expected to last for up to 4 years. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.